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Yaws, a neglected tropical disease caused by the bacterium Treponema pallidum subspecies pertenue, 
predominantly affects children living in low-income, 
rural communities of warm and humid regions (1). 
Clinical manifestations include lesions of the skin, 
bone, and cartilage, progressing to severe destructive 
lesions if left untreated (2). Manifestations of primary 
yaws include papillomas or ulcerative lesions; mani-
festations of secondary yaws include a wide range of 
rashes, often accompanied by bone and joint involve-
ment (2). Currently, 15 countries in West and Cen-
WUDO$IULFD6RXWKHDVW$VLDDQGWKH3DFLÀFUHJLRQDUH
known to be yaws-endemic. The World Health Orga-
nization (WHO) released a yaws eradication strategy 
(the Morges strategy) in 2012 (3). The mainstay of the 
strategy is mass drug administration (MDA) with 
single-dose azithromycin in yaws-endemic commu-
nities, followed by routine surveillance and retreat-
ment for 3–6 months until no cases remain (3).
Serologic tests, including the T. pallidum particle 
agglutination and rapid plasma reagin tests, remain 
the primary diagnostic tools for yaws (2). Newer 
point-of-care serologic tests have replaced traditional 
laboratory-based serologic assays in many settings 
(4–7). Despite their central role in yaws diagnosis, se-
rologic assays have several limitations. First, trepone-
mal serologic assays usually remain positive over a 
patient’s lifetime, and these tests cannot distinguish 
previous from current infection. Second, studies in 
$IULFD DQG LQ FRXQWULHV LQ WKH 3DFLÀF UHJLRQ KDYH
demonstrated that Haemophilus ducreyi causes cutane-
ous lesions similar to those observed in yaws (8–11). 
Persons with clinically suspicious lesions caused by 
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Yaws, a neglected tropical disease caused by the bacte-
rium Treponema pallidum subspecies pertenue, manifests 
DVXOFHUDWLYHVNLQ OHVLRQV1XFOHLFDFLGDPSOL¿FDWLRQWHVWV
OLNHORRSPHGLDWHGLVRWKHUPDODPSOL¿FDWLRQ/$03DUHYHU-
satile tools to distinguish yaws from infections that cause 
similar skin lesions, primarily Haemophilus ducreyi. We de-
veloped a novel molecular test to simultaneously detect T. 
pallidum and H. ducreyi based on mediator displacement 
/$03:HYDOLGDWHGWKHT. pallidum and H. ducreyi/$03
73+'/$03E\WHVWLQJFOLQLFDOVDPSOHVIURPSDWLHQWV
ZLWK\DZVOLNHOHVLRQV&RPSDUHGZLWKTXDQWLWDWLYH3&5WKH
73+'/$03 GHPRQVWUDWHG KLJK VHQVLWLYLW\ DQG VSHFL¿F-
ity for T. pallidum VHQVLWLYLW\VSHFL¿FLW\DQG 
H. ducreyi VHQVLWLYLW\VSHFL¿FLW\7KLVQRYHO
DVVD\SURYLGHGUDSLGPROHFXODUFRQ¿UPDWLRQRIT. pallidum 
and H. ducreyi DNA and might be suitable for use at the 
SRLQWRIFDUH73+'/$03FRXOGVXSSRUW\DZVHUDGLFDWLRQ
by improving access to molecular diagnostic tests at the dis-
trict hospital level.
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H. ducreyi can have a reactive serologic test for yaws 
because of latent T. pallidum infection. Nucleic acid 
DPSOLÀFDWLRQ WHVWV 1$$7V FDQ GLVWLQJXLVK DFWLYH
yaws, involving a lesion with detectable T. pallidum 
DNA, from latent yaws, in which patients will have 
reactive serology without detectectable T. pallidum 
DNA from lesions. In addition, before seroconver-
sion, a small proportion of patients with early active 
yaws will have a positive NAAT but negative sero-
logic results.
NAATs could play a central role in yaws eradica-
tion efforts, particularly for diagnosis and surveillance 
after MDA in yaws-endemic areas (12). PCR has been 
standard for molecular diagnosis and has a high speci-
ÀFLW\DQGVHQVLWLYLW\IRUT. pallidum and H. ducreyi, but 
the process is time-consuming and requires expensive 
laboratory equipment. Most yaws-endemic coun-
tries have limited access to PCR to aid national yaws 
eradication programs. A point-of-care NAAT could 
provide reliable post-MDA molecular surveillance, as 
well as help in monitoring for azithromycin resistance. 
/RRSPHGLDWHG LVRWKHUPDO DPSOLÀFDWLRQ /$03 LV
an alternative for molecular diagnosis that might be 
more suitable than PCR as a point-of-care NAAT in re-
source-limited environments. LAMP has fast process-
LQJ WLPHVDQGKLJKVSHFLÀFLW\DQGFDQEHSHUIRUPHG
on less expensive devices than those needed for PCR. 
Multiplex technologies, such as mediator displace-
ment (MD) LAMP (13), have extended the usability 
of LAMP for simultaneous detection of >1 target and 
FRXOG EH DQ HIÀFLHQW DQG FRVWHIIHFWLYH VROXWLRQ0'
detection uses an MD probe composed of a generic 
mediator attached to a generic overhang of a DNA 
WDUJHWVSHFLÀFVHTXHQFHDQGDXQLYHUVDOUHSRUWHUPRO-
HFXOHZLWKDÁXRURSKRUHDQGTXHQFKHUIRUGHWHFWLRQ
We developed and validated a biplex MD LAMP assay 
to simultaneously identify T. pallidum and H. ducreyi. 
Methods
Participants
We obtained samples from larger trials conducted 
on Lihir Island (n = 57) and Karkar Island (n = 184), 
Papua New Guinea; and in Ghana (n = 52). Details 
of the studies in which the samples were collected 
are provided elsewhere (14,15). In brief, samples 
were collected as part of a randomized control trial 
comparing azithromycin doses of 30 mg/kg against 
doses of 20 mg/kg to treat patients in a pilot study 
for yaws elimination (14,15). Swabs were collected 
from persons with yaws-like ulcers and placed in 
AssayAssure Multilock (Sierra Molecular, https://
sierramolecular.com) transport medium, then frozen 
at –20°C until transported to Mast Diagnostica GmbH 
laboratory in Reinfeld, Germany. DNA was extracted 
from the samples by using innuPREP MP Basic Kit A 
(Analytik Jena, https://www.analytik-jena.com) ac-
cording to manufacturer’s instructions. Isolated DNA 
was kept frozen at –20°C until it was used for biplex 
T. pallidum and H. ducreyi LAMP (TPHD-LAMP), sin-
gleplex T. pallidum and H. ducreyi LAMP assays, and 
quantitative PCR (qPCR) testing.
Ethics Approval
Participants, or parents or guardians of persons <18 
years of age, provided written consent for inclusion 
in clinical surveys and etiologic studies. Children also 
provided assent when appropriate. The studies were 
approved by the National Medical Research Advi-
sory Committee of the Papua New Guinea Ministry 
of Health (MRAC nos. 12.36 and 14.31), the Ghana 
Health Service (approval no. GHS 13/11/14), the 
London School of Hygiene & Tropical Medicine (ap-
proval no. 8832), and WHO (approval no. RPC720).
TPHD-LAMP Assay
We devised the TPHD-LAMP assay on the basis of 2 
previously published assays: a singleplex LAMP as-
say (16ZKLFKZHPRGLÀHGE\DGGLQJDQ0'SUREH
and a biplex LAMP assay of T. pallidum and H. ducreyi 
(13). TPHD-LAMP primers target the polymerase I 
(polA) gene of T. pallidum and the 16S ribosomal RNA 
(16S rRNA) of H. ducreyi. We further optimized the as-
says for improved functionality by redesigning prim-
ers and probes and modifying reagent concentrations 
(Appendix Tables 1–3, https://wwwnc.cdc.gov/
EID/article/26/2/19-0505-App1.pdf). 
We performed a 2-step validation of the TPHD-
/$03DVVD\,QWKHÀUVWVWHSZHDVVHVVHGWKHDQDO\WL-
FDOVHQVLWLYLW\DQGVSHFLÀFLW\RIWKHDVVD\,QWKHVHF-
ond step, we used clinical samples collected in Ghana 
and Papua New Guinea to compare the performance 
of TPHD-LAMP against qPCR for individual targets. 
In a secondary analysis, we compared the perfor-
mance of singleplex LAMP assays for each individual 
target against qPCR assays.
Assessment of Analytical Performance
We determined the analytical limit of detection 
(LOD) for the TPHD-LAMP assay by using target 
sequences cloned into plasmids. We determined the 
LOD of each of the 2 components separately, as well 
as the LOD of the biplex TPHD-LAMP assay (Ap-
pendix). We varied the plasmid DNA concentrations 
between 3 × 101 copies/reaction and 3 × 105 copies/
reaction in 8 replicates to reproduce the Treponema 
0XOWLSOH[/$03IRUT. pallidum and H. ducreyi
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bacterial load in skin infections, which ranges from 
102–104 copies/reaction (17). In addition, we tested 
the TPHD-LAMP in the presence of a high number 
of copies, 3 × 105 copies/reaction, of H. ducreyi or 
T. pallidum in the presenece of a low number of cop-
ies of the second target to optimize each component 
and to simulate clinical samples that might contain 
both targets. We conducted primer titration experi-
PHQWVWRPLQLPL]HWKHSUHIHUHQWLDODPSOLÀFDWLRQRI
H. ducreyi DNA targets in persons with both infec-
tions. We estimated the LOD by counting the frac-
WLRQRISRVLWLYHDPSOLÀFDWLRQVDQGSHUIRUPHGSURELW
regression analysis by using SPSS Statistics 25 (IBM, 
https://www.ibm.com).
:H DVVHVVHG WKH DQDO\WLFDO VSHFLÀFLW\ RI WKH
primer sets in silico by using ortholog target gene 
sequences from GenBank (Appendix Table 4) and 
IRXQG DOO SULPHU VHWV ZHUH KLJKO\ VSHFLÀF IRU T. 
pallidum and H. ducreyi. Based on these results, 
ZH WHVWHG WKH VSHFLÀFLW\ RI 73+'/$03 LQ YLWUR
against endemic pathogens associated with cuta-
neous ulcerative syndromes by using a panel of 13 
organisms: Escherichia coli, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, 
Enterobacter cloacae, Salmonella enterica (Paratyphi 
and Typhi), Streptococcus pneumoniae, Streptococ-
cus pyogenes, Staphylococcus aureus, Corynebacterium 
diphtheria, Corynebacterium ulcerans, Proteus mirabilis, 
and Enterococcus faecalis (Appendix). We calculated 
interassay and intraassay variability of the TPHD-
LAMP assay by using 3 batches of the TPHD-LAMP 
mix, prepared individually on 3 separate days 
and processed in different runs of 3 replicates per 
batch (Appendix).
Clinical Performance of the TPHD-LAMP
We performed clinical validation by comparing the 
performance of the TPHD-LAMP and qPCR assays to 
identify T. pallidum and H. ducreyi in patient samples 
collected in Ghana and Papua New Guinea. TPHD-
LAMP reactions (10 µL per assay) were composed 
of 1× RM MPM buffer (MAST Diagnostica GmbH, 
https://mast-group.com), 8 U Bst 2.0 WarmStart 
DNA Polymerase (New England Biolabs, https://
www.neb.com), 0.05 µmol/L universal reporter, and 
MD primer mix (Appendix). We incubated primer 
mixes for 5 m at 70°C before LAMP to prevent non-
VSHFLÀF DPSOLÀFDWLRQ LQLWLDWHG E\ SULPHU GLPHUL]D-
tion. We performed real-time TPHD-LAMP reactions 
at 64°C in a Rotor-Gene Q (QIAGEN, https://www.
TLDJHQFRPDQGDFTXLUHGÁXRUHVFHQFHVLJQDOVHYHU\
minute by using the Cy5-readout gain for T. pallidum 
and the FAM-readout gain for H. ducreyi. The single-
plex LAMP reactions (10 µL per assay) using inter-
calating dye were composed of 1× RM MPM buffer, 
8 U Bst 2.0 WarmStart DNA Polymerase, and 1 µL 
of 10× SYBR Green staining reagent, DNA free (Ap-
pliChem, https://www.applichem.com) and primer 
mix (Appendix Table 1). We also performed single-
plex LAMP reactions in a Rotor-Gene Q at 63°C with 
the FAM-readout gain. We used a cutoff of 60 m for 
biplex TPHD-LAMP and singleplex LAMP assays 
DQG FRQVLGHUHG VDPSOHV ZLWK DPSOLÀFDWLRQ EH\RQG
60 m negative.
For performance analyses, we compared the 
TPHD-LAMP assay against TaqMan qPCR assays 
targeting polA of T. pallidum (18) and an optimized 
TaqMan qPCR assay targeting the 16S rRNA gene of 
H. ducreyi on the same DNA extract (Appendix Table 
4, Figure 1). The 16S rRNA gene has been previously 
used in qPCR assays to detect H. ducreyi (19). We ran 
all tests in duplicate and included positive controls 
and DNA-free negative controls in each run. We 
used an identical sample volume, 2.5 µL/reaction, 
for TPHD-LAMP, singleplex LAMP, and qPCR. For 
samples that tested negative by qPCR but positive by 
TPHD-LAMP, we repeated qPCR in a single reaction 
with higher sample volumes (3 µL) to identify true 
negative test results.
Statistical Analysis
For clinical validation, we compared the sensitivity 
DQGVSHFLÀFLW\RIWKH73+'/$03DVVD\DJDLQVW7DT-
Man qPCR assays. In a secondary analysis, we com-
pared the performance of singleplex LAMP assays to 
qPCR. We performed all analysis by using R version 
3.4.3 (https://www.R-project.org).
Results
$QDO\WLFDO6HQVLWLYLW\DQG6SHFL¿FLW\
The LOD for the TPHD-LAMP assay was 357 copies/
reaction (95% CI 265–535 copies/reaction) for T. palli-
dum and 293 copies/reaction (95% CI 199–490 copies/
reaction) for H. ducreyi. When we added the second 
target at the higher concentration of 3 × 105 copies/
reaction to simulate clinical samples from persons in-
fected with both bacteria, the LOD increased to 808 
copies/reaction (95% CI 550–2,128 copies/reaction) 
for T. pallidum and 622 copies/reaction (95% CI 415–
1,687 copies/reaction) for H. ducreyi (Appendix Fig-
ure 2). The TPHD-LAMP assay was negative for all 
other pathogens tested within 60 m, demonstrating 
KLJK DQDO\WLFDO VSHFLÀFLW\ $SSHQGL[ )LJXUH :H
observed a minimal interassay or intraassay variation 
(Appendix Figure 4).
 (PHUJLQJ,QIHFWLRXV'LVHDVHVZZZFGFJRYHLG9RO1R)HEUXDU\ 
0XOWLSOH[/$03IRUT. pallidum and H. ducreyi
Validation of TPHD-LAMP in Clinical Samples
For clinical validation, we used a sample set consist-
ing of 293 lesion swabs collected from patients with 
suspected T. pallidum infection. Samples were collect-
ed in Lihir Island (n = 57; 19.5%) and Karkar Island (n 
= 184; 62.8%), Papua New Guinea; and in Ghana (n = 
52; 17.7%). A total of 184 (62.8%) cases were in male 
patients and 109 (37.2%) in female patients; the me-
dian age of case-patients was 10 years (interquartile 
range [IQR] 8–12 years).
Using qPCR, we detected T. pallidum in 59 (20.1%) 
samples, H. ducreyi in 155 (52.9%) samples, and T. pal-
lidum and H. ducreyi co-infection in 19 (6.5%) samples. 
When tested by TPHD-LAMP, we detected T. pallidum 
in 60 (20.5%) samples and H. ducreyi in 163 (55.6%) 
samples. We detected both targets in 12 (4.1%) sam-
ples. Taking qPCR as the reference standard, the diag-
nostic sensitivity of the TPHD-LAMP assay for T. pal-
lidumZDVDQGWKHVSHFLÀFLW\ZDV)RUH. 
ducreyi, the sensitivity of the TPHD-LAMP assay was 
DQGWKHVSHFLÀFLW\ZDV7DEOH.DSSD
FRHIÀFLHQWVǋUDQJLQJIURPWRIRUWKHGHWHFWLRQ
of T. pallidum and from 0.7 to 0.8 for H. ducreyi, show 
substantial to excellent agreement between qPCR and 
TPHD-LAMP. Moderate agreement between qPCR 
DQG73+'/$03ǋ DOVRZDVGHPRQVWUDWHGIRU
the simultaneous detection of both targets. The medi-
DQWLPHWRDPSOLÀFDWLRQRIT. pallidum was 11 min (IQR 
²PLQDQGWKHPHGLDQWLPHWRDPSOLÀFDWLRQRIH. 
ducreyi was 10 min (IQR 8–24 min).
For samples in which only 1 organism was de-
tected by qPCR, the sensitivity of the TPHD-LAMP 
assay was higher for both T. pallidum (92.5%) and H. 
ducreyi (94.1%) than for samples with both organisms 
FRQÀUPHGE\T3&5)RU VDPSOHV FRQÀUPHG WR FRQ-
tain both bacteria by qPCR, sensitivity for T. pallidum 
was 68.4% (p = 0.048) and sensitivity for H. ducreyi 
was 73.7% (p = 0.01) (Table 1).
Using qPCR as the reference standard, the single-
plex T. pallidum LAMP assay had a sensitivity of 78.0% 
DQGVSHFLÀFLW\RIIRUWKHVLQJOHSOH[H. ducreyi 
/$03DVVD\WKHVHQVLWLYLW\ZDVDQGVSHFLÀFLW\
was 75.3% (Table 2). We did not see a noticeable vari-
ation in the performance of the biplex TPHD-LAMP 
and singleplex LAMP assays between locations from 
which samples were collected (Tables 1 and 2).
Discussion
We provide data demonstrating a high analyti-
cal performance of a multiplex LAMP assay for T. 
pallidum and H. ducreyi and a high sensitivity and 
VSHFLÀFLW\ FRPSDUDEOH WR T3&5 7KH 73+'/$03
assay also performed better than singleplex LAMP 
DVVD\V OLNHO\ UHÁHFWLQJ EHWWHU SHUIRUPDQFH RI WKH
MD technology used in the biplex LAMP compared 
with standard intercalating dyes used in singleplex 
LAMP assays. 
The LOD of the TPHD-LAMP assay was 300 cop-
ies/reaction for both targets, which is comparable to 
qPCR, which has standard reproducibility in a range 
 
Table 1. Comparison of clinical performance of biplex loop-mediated isothermal amplification for detection of Treponema pallidum and 
Haemophilus ducreyi 73+'-/$03against singleplex TaqMan quanWLWDWLYH3&5 
Characteristics 6DPSOHVL]H Treponema pallidum Haemophilus ducreyi 
Total samples, no.    
 No. positive  60  
 6HQVLWLYLW\&,  – – 
 6SHFLILFLW\&,  – 84.8 (77.4– 
Lesions containing a single pathogen†    
 No. positive  48  
 6HQVLWLYLW\&,  – – 
 6SHFLILFLW\&,  – 84.8 (77.4– 
Lesions containing both pathogens†    
 No. positive  12 12 
 6HQVLWLYLW\&,  –86.4) – 
 6SHFLILFLW\&,  NA NA 
Samples from Lihir Island, no.     
 No. positive  21  
 6HQVLWLYLW\&,  – – 
 6SHFLILFLW\&,  – –100) 
Samples from Karkar Island, no.  184   
 No. positive    
 6HQVLWLYLW\&,  – – 
 6SHFLILFLW\&,  – – 
6DPSOHVIURP*KDQDQR    
 No. positive   6  
 6HQVLWLYLW\&,  –100) – 
 6SHFLILFLW\&,  –100) – 
1$QRWDSSOLFDEOH 
†Determined by quantitative PCR. 
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of 101–106 copies/reaction. The LOD increased to 
§FRSLHVUHDFWLRQLQVDPSOHVWKDWFRQWDLQHGERWK
targets, which is consistent with our clinical valida-
tion of the TPHD-LAMP; sensitivity for both bacteria 
was slightly higher when samples contained only a 
VLQJOH WDUJHW.DSSD FRHIÀFLHQWV FRQÀUPHG VXEVWDQ-
WLDODJUHHPHQWǋ!IRUWKHLQGLYLGXDOWDUJHWVDQG
PRGHUDWHDJUHHPHQWǋ IRUVLPXOWDQHRXVGHWHF-
tion of both targets in a sample. 
Detection of T. pallidum is the programmatic pri-
ority, but detection of H. ducreyi LVEHQHÀFLDOIRUFOLQL-
cal management of patients with suspected yaws. The 
PHGLDQWLPHWRDPSOLÀFDWLRQZDVPIRUERWKT. 
pallidum and H. ducreyi, indicating the TPHD-LAMP 
DVVD\FRXOGSURYLGHUDSLGPROHFXODUFRQÀUPDWLRQRI
the presence of T. pallidum or H. ducreyi. Further op-
timization of the assay to enhance the performance 
of the T. pallidum component, particularly in the con-
text of co-infection, will be required to ensure cases of 
yaws are not missed.
Implementing qPCR at the point of care is oper-
ationally challenging because it requires relatively 
expensive equipment, in particular thermocyclers, 
which can cost up to 10 times as much as a tubescan-
ner capable of performing the TPHD-LAMP assay. 
Because qPCR is available only in a limited number 
of national and international reference laboratories, 
TPHD-LAMP might be an alternative molecular test 
to support expansion of yaws eradication activities. 
We did not conduct a cost-effectiveness analysis 
of the TPHD-LAMP assay, but such an assessment 
should consider equipment costs, cost per assay, 
and the relative performance of each assay to assess 
the cost per case diagnosed. However, our data sug-
gest that the TPHD-LAMP assay might be a cost-
saving alternative to qPCR, especially at the point 
of care.
Our study had some limitations. We tested 
samples from only 2 geographic regions for clinical 
validation of the TPHD-LAMP. Primer binding site 
mutations have affected the performance of other di-
agnostic assays for T. pallidum strains. Although we 
selected conserved genomic regions when design-
ing the TPHD-LAMP primers, further experimental 
validation of the TPHD-LAMP assay with samples 
from a broader range of settings is needed. We con-
ducted clinical validation of the assay in a controlled 
laboratory setting, but conditions at the point of 
care, including temperature, humidity, and a range 
of other environmental factors, might affect reagents 
in storage and in performing assays. Further opti-
mization, including freeze-dried reagents in combi-
nation with dried oligonucleotides, might improve 
robustness and facilitate rollout of the assay in yaws- 
endemic countries.
In yaws-endemic countries, clinical manifesta-
tions combined with serologic tests are still the stan-
dard tool for the clinical management of yaws, but 
serologic tests have limitations and molecular assays 
are needed to support WHO yaws eradication efforts 
(12). Molecular assays also can detect mutations in 
the 23S RNA gene associated with azithromycin re-
sistance (15,20,21), which is essential to monitor for 
drug resistance as yaws eradication efforts expand. 
qPCR is the most common NAAT currently avail-
able but remains restricted to a small number of 
laboratories in yaws-endemic countries. MD LAMP 
could facilitate surveillance for resistance and we 
SODQ IXUWKHU VWXGLHV WRHYDOXDWHDPRGLÀHG73+'
LAMP assay for this purpose. Further, multicountry 
evaluations are warranted to assess performance of 
the assay when deployed in yaws-endemic countries 
and to assess the role the test could play in support 
of national yaws eradication programs. Nonetheless, 
the performance characteristics of the TPHD-LAMP 
suggest it has the potential to increase access to mo-
lecular diagnosis of yaws, especially at the point 
of care. 
 
Table 2. Comparison of clinical performance of singleplex loop-mediated isothermal amplification for detection of Treponema pallidum 
and Haemophilus ducreyi DJDLQVWVLQJOHSOH[7DT0DQTXDQWLWDWLYH3&5 
Characteristics 6DPSOHVL]H Treponema pallidum Haemophilus ducreyi 
Total samples, no.    
 No. positive     
 6HQVLWLYLW\&,  – – 
 6SHFLILFLW\&,  – –82.1) 
Lesions containing a single pathogen†    
 No. positive     
 6HQVLWLYLW\&,  – – 
 6SHFLILFLW\&,  – –82.1) 
Lesions containing both pathogens†    
 No. positive samples  17 17 
 6HQVLWLYLW\&,  –86.4) – 
 6SHFLILFLW\&,  NA NA 
1$QRWDSSOLFDEOH 
†Determined by quantitative PCR. 
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